MA56462A - Inhibiteurs de hpk1 et leurs utilisations - Google Patents
Inhibiteurs de hpk1 et leurs utilisationsInfo
- Publication number
- MA56462A MA56462A MA056462A MA56462A MA56462A MA 56462 A MA56462 A MA 56462A MA 056462 A MA056462 A MA 056462A MA 56462 A MA56462 A MA 56462A MA 56462 A MA56462 A MA 56462A
- Authority
- MA
- Morocco
- Prior art keywords
- hpk1 inhibitors
- hpk1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019094634 | 2019-07-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56462A true MA56462A (fr) | 2022-05-11 |
Family
ID=74100919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056462A MA56462A (fr) | 2019-07-04 | 2020-07-03 | Inhibiteurs de hpk1 et leurs utilisations |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12612424B2 (fr) |
| EP (2) | EP3994133A4 (fr) |
| JP (2) | JP7633989B2 (fr) |
| KR (2) | KR20220044495A (fr) |
| CN (2) | CN114555585B (fr) |
| AU (2) | AU2020298649B2 (fr) |
| BR (1) | BR112022000064A2 (fr) |
| CA (1) | CA3145973A1 (fr) |
| DK (1) | DK4175951T3 (fr) |
| ES (1) | ES2981368T3 (fr) |
| FI (1) | FI4175951T3 (fr) |
| IL (1) | IL289612B2 (fr) |
| MA (1) | MA56462A (fr) |
| MX (2) | MX2022000271A (fr) |
| TW (1) | TWI878319B (fr) |
| WO (2) | WO2021000935A1 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211655A1 (es) | 2018-10-31 | 2021-08-24 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| WO2020092528A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| US12612424B2 (en) | 2019-07-04 | 2026-04-28 | Regor Pharmaceuticals, Inc. | HPK1 inhibitors and uses thereof |
| TW202140473A (zh) | 2020-01-15 | 2021-11-01 | 美商纜圖藥品公司 | Map4k1抑制劑 |
| WO2022063140A1 (fr) * | 2020-09-23 | 2022-03-31 | Shenzhen Ionova Life Science Co., Ltd. | Dérivés de pyrimidine et de pyridine en tant que modulateurs de hpk1 et leurs procédés d'utilisation |
| CN116874503B (zh) * | 2020-10-28 | 2025-08-08 | 杭州阿诺生物医药科技有限公司 | 一种高活性的hpk1激酶抑制剂 |
| WO2022174253A1 (fr) * | 2021-02-12 | 2022-08-18 | Nimbus Saturn, Inc. | Antagonistes de hpk1 et leurs utilisations |
| CN117295737A (zh) * | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| EP4305041A1 (fr) * | 2021-03-08 | 2024-01-17 | Blueprint Medicines Corporation | Inhibiteurs de map4k1 |
| CN117295748A (zh) * | 2021-03-08 | 2023-12-26 | 缆图药品公司 | Map4k1抑制剂 |
| WO2022199561A1 (fr) * | 2021-03-23 | 2022-09-29 | 杭州阿诺生物医药科技有限公司 | Composé inhibiteur de la kinase hpk1 |
| WO2022213062A1 (fr) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Antagonistes de hpk1 et leurs utilisations |
| CN117377673A (zh) * | 2021-03-29 | 2024-01-09 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| TW202304906A (zh) * | 2021-04-08 | 2023-02-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 高活性hpk1激酶抑制劑 |
| MX2024000751A (es) | 2021-07-14 | 2024-03-25 | Blueprint Medicines Corp | Compuestos heterociclicos como inhibidores de map4k1. |
| EP4373817B1 (fr) | 2021-07-20 | 2025-05-21 | Astrazeneca AB | Pyrazine-2-carboxamides substituées utilisées en tant qu'inhibiteurs de hpk1 pour le traitement du cancer |
| WO2023083299A1 (fr) * | 2021-11-12 | 2023-05-19 | 微境生物医药科技(上海)有限公司 | Composé cyclique fusionné utilisé en tant qu'inhibiteur de hpk1 |
| WO2023134608A1 (fr) * | 2022-01-11 | 2023-07-20 | 微境生物医药科技(上海)有限公司 | Composés cycliques fusionnés servant d'inhibiteurs de hpk1 |
| WO2023245329A1 (fr) * | 2022-06-20 | 2023-12-28 | Biofront Ltd | Inhibiteurs de kinases multiples, compositions de ceux-ci et leurs procédés d'utilisation |
| CN117447479B (zh) * | 2023-02-20 | 2026-01-20 | 杭州医学院 | 一种靶向肿瘤免疫激酶的吡咯并吡嗪衍生物、制备方法及其应用 |
| CN116813692A (zh) * | 2023-06-29 | 2023-09-29 | 凌科药业(杭州)有限公司 | 含磷化合物、其药物组合物及其用途 |
| WO2025096647A1 (fr) * | 2023-10-30 | 2025-05-08 | Nimbus Saturn, Inc. | Méthodes de traitement de tumeurs |
| WO2025137168A2 (fr) | 2023-12-19 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Formes salines et solides d'un inhibiteur de hpk1 |
| WO2025255343A1 (fr) * | 2024-06-06 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de pyrrolopyrimidine de lrrk2 de type sauvage et mutant |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028724A1 (fr) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Inhibiteurs de la kinase chk1 |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2007041511A2 (fr) | 2005-09-30 | 2007-04-12 | New York University | Kinase des progeniteurs hematopoietiques 1 destinee a la modulation d'une reponse immune |
| US20090306126A1 (en) | 2006-05-22 | 2009-12-10 | Astrazeneca Ab | Indole Derivatives |
| US8258129B2 (en) * | 2006-07-06 | 2012-09-04 | Boehringer Ingelheim International Gmbh | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
| WO2008079988A2 (fr) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines destinés à l'inhibition de pdk1 |
| WO2008110508A1 (fr) | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Composés |
| EP2226315A4 (fr) | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | Dérivé de 2-aminoquinazoline |
| US20100121052A1 (en) | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| EP2248907A1 (fr) | 2009-05-08 | 2010-11-10 | Rijksuniversiteit Groningen | Gluco-oligosaccharides comprenant des liens (alpha 1-->4) et (alpha 1-->6) glycosidiquues, leur utilisation et procédés de fabrication |
| US8791112B2 (en) * | 2011-03-30 | 2014-07-29 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| US9708336B2 (en) | 2014-01-22 | 2017-07-18 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
| CN104876914B (zh) | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| US20170137426A1 (en) | 2014-03-28 | 2017-05-18 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
| CN106188029B (zh) * | 2015-05-05 | 2018-09-18 | 山东轩竹医药科技有限公司 | 二并环类间变性淋巴瘤激酶抑制剂 |
| WO2017222287A1 (fr) | 2016-06-20 | 2017-12-28 | 재단법인 대구경북첨단의료산업진흥재단 | Nouveau dérivé d'imidazopyridine, son procédé de préparation, et composition pharmaceutique contenant celui-ci comme principe actif pour la prévention ou le traitement du cancer |
| WO2018002219A1 (fr) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Nouveaux dérivés de cyanoindoline comme inhibiteurs de nik |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy |
| JP7025426B2 (ja) * | 2016-11-30 | 2022-02-24 | アリアド ファーマシューティカルズ， インコーポレイテッド | 造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ |
| WO2018152220A1 (fr) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Composés de pyrazolopyridine et leurs utilisations |
| WO2018155916A2 (fr) | 2017-02-22 | 2018-08-30 | 재단법인 대구경북첨단의료산업진흥재단 | Composé dérivé de pyrrolo-pyrimidine, son procédé de préparation, et composition pharmaceutique comprenant ledit composé en tant que principe actif pour la prévention ou le traitement d'une maladie liée à la protéine kinase |
| JP7132937B2 (ja) * | 2017-03-15 | 2022-09-07 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｐｋ１の阻害剤としてのアザインドール |
| US20200071326A1 (en) | 2017-04-14 | 2020-03-05 | Syros Pharmaceuticals, Inc. | Tam kinase inhibitors |
| JP2021506735A (ja) | 2017-05-26 | 2021-02-22 | イクノス サイエンシズ エスエー | 新規ｍａｐ４ｋ１阻害剤 |
| WO2019074979A1 (fr) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | Composés hétérocycliques et leurs utilisations |
| CN109721620B (zh) | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
| WO2019090198A1 (fr) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Composés d'isofuranone utiles en tant qu'inhibiteurs de hpk1 |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| US20220242870A1 (en) | 2019-05-17 | 2022-08-04 | Voronoi Inc. | Heterocycle-fused pyrimidine derivative and use thereof |
| US12612424B2 (en) | 2019-07-04 | 2026-04-28 | Regor Pharmaceuticals, Inc. | HPK1 inhibitors and uses thereof |
-
2020
- 2020-07-03 US US17/624,514 patent/US12612424B2/en active Active
- 2020-07-03 MX MX2022000271A patent/MX2022000271A/es unknown
- 2020-07-03 BR BR112022000064A patent/BR112022000064A2/pt not_active Application Discontinuation
- 2020-07-03 MA MA056462A patent/MA56462A/fr unknown
- 2020-07-03 AU AU2020298649A patent/AU2020298649B2/en active Active
- 2020-07-03 WO PCT/CN2020/100134 patent/WO2021000935A1/fr not_active Ceased
- 2020-07-03 TW TW109122604A patent/TWI878319B/zh active
- 2020-07-03 KR KR1020227003145A patent/KR20220044495A/ko active Pending
- 2020-07-03 EP EP20834163.6A patent/EP3994133A4/fr active Pending
- 2020-07-03 IL IL289612A patent/IL289612B2/en unknown
- 2020-07-03 JP JP2022500151A patent/JP7633989B2/ja active Active
- 2020-07-03 CN CN202080057904.1A patent/CN114555585B/zh active Active
- 2020-07-03 CA CA3145973A patent/CA3145973A1/fr active Pending
-
2021
- 2021-07-02 WO PCT/CN2021/104206 patent/WO2022002237A1/fr not_active Ceased
- 2021-07-02 AU AU2021299849A patent/AU2021299849A1/en active Pending
- 2021-07-02 CN CN202180053862.9A patent/CN116096370B/zh active Active
- 2021-07-02 MX MX2023000025A patent/MX2023000025A/es unknown
- 2021-07-02 KR KR1020237003551A patent/KR20230035061A/ko active Pending
- 2021-07-02 FI FIEP21742686.5T patent/FI4175951T3/fi active
- 2021-07-02 ES ES21742686T patent/ES2981368T3/es active Active
- 2021-07-02 EP EP21742686.5A patent/EP4175951B1/fr active Active
- 2021-07-02 US US18/013,402 patent/US12617811B2/en active Active
- 2021-07-02 DK DK21742686.5T patent/DK4175951T3/da active
- 2021-07-02 JP JP2023500011A patent/JP7759374B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3994133A4 (fr) | Inhibiteurs de hpk1 et leurs utilisations | |
| EP3972978A4 (fr) | Inhibiteurs de kras g12c et leurs utilisations | |
| EP3746075A4 (fr) | Inhibiteurs de gcn2 et leurs utilisations | |
| EP3870579A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3768664A4 (fr) | Inhibiteurs de shp2 et leurs utilisations | |
| EP4232425A4 (fr) | Inhibiteurs de ctps1 et leurs utilisations | |
| EP3866789A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| MA55565A (fr) | Agents de dégradation de stat et leurs utilisations | |
| EP3886843A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3810182A4 (fr) | Néoantigènes et leurs utilisations | |
| EP3938369A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP4093768A4 (fr) | Constructions cal-t et leurs utilisations | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3624797A4 (fr) | Inhibiteurs de kinase et leurs utilisations | |
| EP3914357A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3389658A4 (fr) | Inhibiteurs de glycosidase et leurs utilisations | |
| EP3860636A4 (fr) | Inhibiteurs de matriptase 2 et leurs utilisations | |
| EP3893945A4 (fr) | Esters cromoglycique et leurs utilisations | |
| EP3870162A4 (fr) | Inhibiteurs de ssao et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP4291235A4 (fr) | Antagonistes de hpk1 et leurs utilisations | |
| EP3976009A4 (fr) | Inhibiteurs de bax et leurs utilisations |